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A B S T R A C T
Introduction: Pregabalin efﬁcacy and safety as an adjunctive treatment for partial seizures was evaluated
using an open-label, ﬂexible-dose.
Study design: In 98 adults with refractory partial epilepsy taking 1–3 anti-epileptic drugs with 2
seizures during an 8-week baseline period.
Methods: Pregabalin was increased to 600 mg/day during a 9-week dose optimization period with
dosage maintained for 12 additional weeks. Primary endpoint was the percentage change in partial
seizure frequency between the 8-week baseline and 12-week observation period.
Results: Pregabalin treatment was associated with a signiﬁcant reduction in partial seizure frequency:
median percent change in partial seizure frequency from baseline to 12 weeks was 33% and 22% in
patients with a baseline seizure frequency of 3 and >3 per 28 days, respectively. The 50% and 75%
responder rates were 41.94% (95% CI: 31.91–51.96) and 30.11% (95% CI: 20.78–39.43), respectively.
Nineteen percent of subjects were seizure-free throughout the last 12 weeks. Pregabalin administration
resulted in a signiﬁcant reduction in anxiety (mean reduction in Hospital Anxiety and Depression Scale
scores of 1.68 units, 95% CI: 2.60 to 0.76). Most patients were much improved or very much improved
on Patient Global Impression of Change (53.8%) and Clinical Global Impression of Change (53.8%). The
most frequently self-reported adverse events (AEs) were mild or moderate somnolence (20.4%) and
dizziness (5.1%) with a low AE discontinuation rate (5.1%).
Conclusions: The efﬁcacy and side-effect proﬁle of pregabalin were similar to previous pregabalin
double-blind, controlled studies. Additionally, pregabalin, as an add-on treatment for partial epilepsy,
exhibits signiﬁcant anti-anxiety properties.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy affects about 50 million people worldwide,1 and
partial-onset seizures (including simple partial, complex partial
and secondarily generalized) are the most common. The manage-
ment of patients with partial epilepsies is currently considered
suboptimal, despite the availability of many anti-epileptic drugs
(AEDs). Only 50–75% of patients achieve complete remission from
seizure activity within the ﬁrst 5 years after diagnosis. Amongvier Ltd. All rights reserved.
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refractory to AEDs administered either alone or in combination and
continue to require an additional anti-epileptic treatment.2,3
Pregabalin is a selective a2d ligand of the presynaptic voltage-
gated calcium channels. Binding at this site reduces calcium inﬂux
at hyperexcitable nerve terminals and decreases the release of
neurotransmitters including glutamate, norepinephrine and sub-
stance P. This activity is thought to impart the analgesic, anxiolytic
and anti-epileptic properties of pregabalin.4
Controlled clinical trials have demonstrated that pregabalin is
effective in the treatment of peripheral5 and central6 neuropathic
pain, and in the treatment of generalized anxiety disorder.7
Pregabalin has a favorable pharmacokinetic proﬁle with linear
elimination and is predictable with low intra-subject variability. It
is cleared renally and does not undergo hepatic metabolism.8
Additionally, pregabalin does not interact with other AEDs,9
providing ease of use in the clinic.
Pregabalin was ﬁrst licensed as an adjunctive treatment for
adults with partial seizures, with or without secondary generali-
zation, in Europe and the United States in 2004 based on data from
several double-blind, placebo-controlled, parallel-group, multi-
center studies in patients with refractory partial seizures.10–13
Most clinical trials of pregabalin have been conducted according to
set protocols and using ﬁxed dosages. The objective of this study
was to explore the use of pregabalin in real-world treatment
situations and everyday clinical practice including dose optimiza-
tion and inclusion of a broader range of subjects in the study
population.
2. Methods
2.1. Study population
Patients were males or females, aged 18 years or older, with a
diagnosis of epilepsy with partial seizures not adequately
controlled by one to three AEDs administered as monotherapy
or in combination, within 1 year of study screening. All patients
had a minimum of two partial seizures within 2 months of the
baseline visit. Additionally, eligible patients had no evidence of
progressive neurological disorders, no absence seizures or status
epilepticus within 1 year prior to screening, and no record of
vigabatrin use. Patients using any medication, or with any medical
condition or abnormality that may have increased the risk
associated with study participation, were excluded.
2.2. Study design
This was an open-label, uncontrolled, add-on treatment,
multicenter study in which subjects took pregabalin orally BID
as an add-on treatment for partial seizures. All seizures wereFig. 1. Study protocol timeline and organizatrecorded in a detailed seizure diary by the patient, a trained
observer or a legal guardian. The study was conducted at eight
study centers in Greece and comprised three main phases with a
total treatment duration of 21 weeks: baseline phase of 8 weeks
(historical baseline allowed if medical history could be veriﬁed),
treatment dose-optimization phase of 9 weeks, and treatment
observation phase of 12 weeks (Fig. 1). For patients who
discontinued, pregabalin was withdrawn gradually over a mini-
mum of 1 week; patients returned for a follow-up visit 1 or 2 weeks
after the last dose of pregabalin.
Pregabalin (75 mg and 150 mg capsules) was initiated at
150 mg/day given as BID and increased based on individual
response and tolerability. 75-mg capsules were available up to visit
3 (week 9), and 150-mg capsules were available thereafter. The
maximum dose was 600 mg/day given as BID during the 9-week
dose-optimization period. Dosage changes were separated by 1
week, and 9 weeks were allowed to reach an optimal pregabalin
dosage, which was maintained for 3 months. However, at any time
during the study, patients could have adjustments to dosages
between 150 and 600 mg/day at the discretion of the investigator.
Concomitant AEDs had to remain unchanged throughout the
whole study period.
The study was conducted in compliance with the Declaration of
Helsinki, Good Clinical Practice guidelines, and local laws and
regulations, and received local ethics board approval. The ﬁnal
protocol and informed consent documentation were reviewed and
approved by the Institutional Review Boards and/or Independent
Ethics Committees at each of the investigational centers partici-
pating in the study. Patients or their legal guardian gave written
informed consent. The study was conducted between December
2005 and December 2007.
2.3. Analyses
Efﬁcacy analyses were based on the full analysis set (FAS)/
intent-to-treat (ITT) population (all subjects who received at least
one dose of study treatment and had a minimum of two partial
seizures during the baseline period). For the primary efﬁcacy
endpoint, supportive sensitivity analysis using the per-protocol
population (all subjects in the ITT who completed a minimum of 19
weeks treatment and did not have major protocol deviations) was
performed to assess the robustness of the conclusions.
Seizure rate during the treatment period was calculated on a
last observation carried forward (LOCF) basis. Seizure frequency
was based on the 12 weeks prior to the last dose and was calculated
as total number of partial seizures per 28-day period. To
accommodate the skewed character of seizure frequencies, the
mean 28-day seizure frequency was calculated using a Response
Ratio (RRatio).14 The RRatio is deﬁned as the ratio [(T  B)/
(T + B)]  100, where B = Baseline Seizure Rate and T = Treatmention. V: visit; AEDs: anti-epileptic drugs.
Table 1
Patient and Clinical Global Impression of Change.
Patient Global
Impression of
Change, n (%)
Clinical Global
Impression of
Change, n (%)
Subjects in the FAS/ITT 93 93
Very much improved 14 (15.1) 15 (16.1)
Much improved 36 (38.7) 35 (37.6)
Minimally improved 17 (18.3) 24 (25.8)
No change 9 (9.7) 11 (11.8)
Minimally worse 3 (3.2) 4 (4.3)
Much worse 1 (1.1) 2 (2.2)
Very much worse 0 0
Missing/not done 13 (14.0) 2 (2.2)
FAS: full analysis set; ITT: intent-to-treat.
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change with a range of 100 to 100. Negative values of the RRatio
represent an improvement in seizure rate and positive values
indicate a worsening of seizure rate. The median change from
baseline was also calculated.
The primary endpoint was the percentage change in partial
seizure frequency between the 8-week baseline and the 12-week
observation period. Seizure activity for efﬁcacy assessments was
recorded by the subject or caregiver in the subject’s seizure diary
from Day 1 through the end of the study. Secondary endpoints
included the following: change in partial seizure frequency,
seizure-free patients during the last 4 and 12 weeks of the
observation period, 50% and 75% responder rates, sleep quality
using the Medical Outcomes Study (MOS) – Sleep Scale, Hospital
Anxiety and Depression Scale (HADS) between baseline and visit 4,
Patient Global Impression of Change (PGIC), and Clinical Global
Impression of Change (CGIC). The HADS, which comprises an
anxiety and a depression subscale, was used to investigate various
dimensions of mood.15 The anxiety subscale (HADS-A) assesses
features of a generalized anxiety state, such as restlessness, panic
attacks, anxious thoughts and anxious mood, whereas the
depression subscale (HADS-D) identiﬁes a state of lost interest
and reduced pleasure. Each subscale includes seven items and has
a total score ranging from 0 to 21 with higher scores reﬂecting
poorer psychological well being. On both subscales, a score of 0–7
is considered normal whereas scores 8 represent levels of
pathological anxiety and depression. The PGIC and CGIC are 7-
point scales on which patients and clinicians, respectively, rate
changes from baseline as ‘‘much improved’’ to ‘‘much worse.’’16
Symptoms of depression and anxiety were assessed using the
HADS at visits 1 and 4. Impression of change was assessed by the
subject using the PGIC and by the clinician using the CGIC at visit 4.
All observed or volunteered AEs, regardless of causal relationship
to the study drug, were recorded from the time the subject took
his/her ﬁrst dose through the last subject visit.
3. Results
3.1. Patients
In total, 102 patients were screened and 98 patients received
treatment with pregabalin. Patient mean age was 38.2 years; 70.4%
were 18–44 years and 25.5% were 45–64 years. All patients were
white and equally distributed between males and females. The
mean duration of epilepsy since ﬁrst diagnosis was 21.2 years
(range, 0.6–60.4 years). Patients were receiving the following
primary AEDs at the time of study entry: carbamazepine (33.0%),
levetiracetam (32.0%) and oxcarbazepine (32.0%).
All 98 patients who received treatment were analyzed for
safety, and 93 FAS/ITT patients were assessed for efﬁcacy. A total of
12 patients (12.2%) discontinued treatment including ﬁve (5.1%)
discontinuations due to AEs, four (4.1%) due to lack of efﬁcacy, and
three (3.0%) due to reasons unrelated to treatment.Table 2
Summary of HADS depression and anxiety symptoms subscales.
Pregabalin (n = 93) Baseline Week 21/e
HADS-D score n 88 77 
Mean (SD) 5.35 (3.639) 4.87 (4.13
95% CI 4.58, 6.12 3.93, 5.81 
HADS-A score n 89 77 
Mean (SD) 7.44 (4.445) 5.91 (4.42
95% CI 6.50, 8.38 4.91, 6.92 
CI: conﬁdence interval; HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale
deviation.3.2. Efﬁcacy
The median percent change from baseline to the last 12 weeks
was 33% in the FAS/ITT population in patients with baseline
seizure frequency 3 or less in 28 days, and the mean RRatio in the
FAS/ITT population was 24.93 (95% CI: 43.66 to 6.20). In
patients with baseline seizure frequency more than 3 seizures in
28 days, the median percent change from baseline to the last 12
weeks was 22%, and the mean RRatio was 20.78 (95% CI: 35.24
to 6.33). When both seizure frequency groups were analyzed
together, the mean RRatio was 22.72 (95% CI: 34.16 to 11.28),
which corresponded to a 37% reduction in seizure frequency from
baseline for all ITT patients. When analyzed over the entire 21-
week, open-label period, the mean RRatio of 17.26 (95% CI:
27.36 to 7.15) for both seizure groups (3 and >3 seizures/28
days) again showed a signiﬁcant reduction in partial seizure
frequency.
Overall, 41.94% (95% CI: 31.91–51.96) of patients experienced at
least a 50% reduction in partial seizure frequency between baseline
and the last 12 weeks of treatment (excluding the ﬁrst 3 weeks of
treatment) of the observation period; 30.11% (95% CI: 20.78–39.43)
experienced a seizure reduction of at least 75%. The percentage of
subjects who were seizure-free throughout the last 12-week
observation period was 19%.
The majority of subjects reported improvements in the PGIC
and CGIC by the end of the 21-week observation period. In both
PGIC and CGIC, 54% of scores showed steady improvement during
the course of pregabalin treatment with most patients and
clinicians reporting ‘‘much improved’’ or ‘‘very much improve-
ment.’’ Among the ITT population, 39% of patients and 38% of
clinicians reported that the overall status of patients had much
improved after 21 weeks (Table 1).
Scores on the MOS-sleep scale did not signiﬁcantly improve
from baseline to week 21. HADS anxiety symptoms were
signiﬁcantly reduced by a mean of 1.68 units (95% CI: 2.60 to
0.76) between baseline and the week 21/early termination visit
(Table 2). Symptoms of depression did not signiﬁcantly improve.arly termination Change from baseline to week 21/early termination
76
1) 0.59 (3.442)
1.38, 0.19
76
5) 1.68 (4.037)
2.60, 0.76
; HADS-D: Hospital Anxiety and Depression Scale-depression subscale; SD: standard
Table 3
Incidence and severity of treatment-emergent adverse events occurring in 2 subjects (all causalities).
System organ class
MedDRA preferred term
Total, n (%) Severity
Mild, n Moderate, n Severe, n
Subjects evaluable for adverse event 98 (100)
Gastrointestinal disorders
Constipation 2 (2.0) 1 1 0
General disorders and administration-site conditions
Asthenia 2 (2.0) 1 1 0
Gait disturbance 3 (3.1) 1 2 0
Edema peripheral 2 (2.0) 2 0 0
Investigations
Weight increased 3 (3.1) 1 1 1
Nervous system disorders
Ataxia 2 (2.0) 1 0 1
Convulsions 4 (4.1) 0 4 0
Disturbance in attention 2 (2.0) 1 1 0
Dizziness 5 (5.1) 4 1 0
Headache 2 (2.0) 2 0 0
Somnolence 20 (20.4) 14 6 0
Psychiatric disorders
Agitation 4 (4.1) 3 1 0
MedDRA: Medical Dictionary for Regulatory Activities.
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The most common (>3% incidence) self-reported treatment-
emergent adverse events (AEs) with pregabalin were: somnolence
(20.4%), dizziness (5.1%), convulsions (4.1%), agitation (4.1%) and
gait disturbance/weight gain (both 3.1%) (Table 3). A weight gain of
7% or more was seen in 13 patients (13.3%) with the majority (8
patients, 8.2%) gaining between 7% and 10%. All treatment-
emergent AEs were of mild or moderate intensity. Discontinua-
tions owing to treatment-emergent AEs in the ITT population were
low (5.1%). In total, 3 patients experienced serious AEs during the
study, but 2 were unrelated to use of study drug and 1 was related
to non-compliance with medication. There were no deaths during
the study. Clinically meaningful changes from baseline to last
observation in systolic or diastolic blood pressure, heart rate or
respiration rate were not observed.
4. Discussion
This study underscores the safety and efﬁcacy of pregabalin as
an adjunctive anti-convulsant treatment in typical daily practice
settings. Flexible dosing, which allows clinicians to titrate dose to
efﬁcacy and tolerability, is more relevant to ‘‘real world’’ practice
than ﬁxed-dose regimens commonly used in clinical trials.
Research in this population of Greek subjects supports the
ﬁndings of earlier researchers on the safety and efﬁcacy of
pregabalin as an adjunctive anti-convulsant treatment when used
in an open-label, ﬂexible-dose paradigm for the treatment of
patients with partial seizures.10–13 For all ITT patients, pregabalin
treatment yielded a signiﬁcant reduction of 37% in partial seizure
frequency between baseline and the last 12 weeks of treatment.
Pregabalin treatment also yielded a signiﬁcant reduction from
baseline in partial seizure frequency throughout the 21-week
treatment period. The majority of patients reported improvements
in PGIC and CGIC by the end of the 21-week observation period,
indicating satisfaction with treatment.
Adverse effects of anti-epileptic drugs are a particular
concern in patients with epilepsy, due to their high frequency
and strong association with poor health-related quality of life
(HRQOL).17 It is clear, therefore, that AEDs with a favorable side-
effect proﬁle are of utmost importance to the optimal manage-
ment of epilepsy particularly in an add-on setting as multidrug
treatment increases the risk of toxicity. In the present study,most side effects were mild to moderate in intensity leading to
discontinuation in 5.1% of patients. This discontinuation rate
related to adverse effects was lower than in controlled studies,
as expected in daily clinical practice, but similar to that of
ﬂexible dose studies.4,13 On the other hand, it should be
acknowledged that AEs in the present study were either
observed by caregivers or were volunteered by the patients
themselves. Therefore, the absence of a structured questionnaire
for AEs, which has been previously shown to detect increased
rates of AEs compared to spontaneous reporting,18 may have
contributed, to some extent, to the favorable AE proﬁle.
The observed reduction in the levels of anxiety after the
administration of pregabalin merits further discussion. Anxiety is a
common emotional problem in patients with epilepsy, occurring in
25% of epileptic subjects in a community setting,19 whereas in
secondary care and specialist centers its prevalence exceeds
50%.20,21 In our cohort, 49% of subjects suffered from anxiety
(HADS-A scores 8). Of particular clinical importance is the recent
ﬁnding that anxiety exerts a profound negative effect on the
HRQOL in patients with epilepsy. A number of studies22,23
demonstrated that anxiety and depression explain more variance
in HRQOL than any other seizure-related or demographic variable.
It is conceivable, therefore that AEDs with anti-anxiety properties
may be particularly beneﬁcial for patients with epilepsy. Currently,
there is no clear, evidence-based therapeutic strategy for treating
anxiety in patients with epilepsy. Over the years, the mainstay of
treatment has been the use of benzodiazepines, due to their potent
anti-convulsant and anti-anxiety properties. Their use, however,
should be avoided over prolonged periods due to the danger of
dependence and potential of withdrawal seizures.24 Alternatively,
selective serotonin re-uptake inhibitors may be used; however,
these agents have a delayed onset of action and are associated with
a small risk of seizure exacerbation. Our data suggest that
pregabalin as an add-on treatment is a reasonable choice for
patients with partial epilepsy who have concomitant symptoms of
an anxiety disorder.
Our research is limited by the short observation period and,
most importantly, by the lack of a control group, which limits the
extent to which the results can be generalized. ‘‘Real world’’
studies such as this provide useful insight into the use of
pregabalin in typical clinical situations; however, comparisons
of the results of this study with earlier controlled trials of
pregabalin should be made with caution.
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This 21-week, open label study adds to the accumulating
evidence of the efﬁcacy and safety of pregabalin as an adjunctive
treatment for partial seizures.10–13,25–30 As demonstrated by this
research in everyday clinical practice, seizure frequency was
reduced by 37% with more than half of patients and clinicians
reporting ‘‘much improved’’ or ‘‘very much improvement.’’
Additionally, pregabalin, as an add-on treatment in patients with
partial epilepsy, exhibited signiﬁcant anti-anxiety properties.
Sources of funding
This study was funded by Pﬁzer Inc. LL and BE are full time-
employees of Pﬁzer Inc. All other authors were investigators in the
study, but were not compensated to develop this manuscript. ST
has received research funding from Pﬁzer and Arriani Pharma-
ceuticals, as well as funding from Novartis and Janssen as an
advisory board member. VK has received research funding from
Pﬁzer, Janssen-Cilag, BIAL, EISAI and the National Scholarships
Foundation. Other authors reported no conﬂicts of interest.
Acknowledgements
Editorial support was provided by Gayle Scott, PharmD of UBC
Scientiﬁc Solutions and funded by Pﬁzer Inc. BE, a Pﬁzer employee,
provided statistical analysis. LL, a Pﬁzer employee, was involved in
the interpretation of the data and preparation of the manuscript.
References
1. Brodie MJ, Shorvon SD, Canger R, Hala´sz P, Johannessen S, Thompson P, et al.
Commission on European affairs: appropriate standards of epilepsy care across
Europe: ILEA. Epilepsia 1997;38:1245–50.
2. Kwan P, Brodie MJ. Early identiﬁcation of refractory epilepsy. The New England
Journal of Medicine 2000;342:314–9.
3. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of
epilepsy: results from the National General Practice Study of Epilepsy. Lancet
1995;346:140–4.
4. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of
pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target
for antiepileptic drug discovery. Epilepsy Research 2007;73:137–50.
5. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efﬁcacy of prega-
balin in neuropathic pain evaluated in a 12-week, randomised, double-blind,
multicentre, placebo-controlled trial of ﬂexible- and ﬁxed-dose regimens. Pain
2005;115:254–63.
6. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in
central neuropathic pain associated with spinal cord injury: a placebo-con-
trolled trial. Neurology 2006;67:1792–800.
7. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efﬁcacy and safety
of pregabalin in the treatment of generalized anxiety disorder: a 6-week,
multicenter, randomized, double-blind, placebo controlled comparison of preg-
abalin and venlafaxine. The Journal of Clinical Psychiatry 2006;67:771–82.
8. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical prac-
tice. Epilepsia 2004;45(Suppl. 6):13–8.9. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, et al.
Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of
carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial
epilepsy. Epilepsia 2005;46:1407–13.
10. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin
add-on treatment: a randomized, double-blind, placebo-controlled, dose–re-
sponse study in adults with partial seizures. Epilepsia 2004;45:20–7.
11. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety
and efﬁcacy of two pregabalin regimens for add-on treatment of partial
epilepsy. Neurology 2005;64:475–80.
12. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose–response trial of
pregabalin adjunctive therapy in patients with partial seizures. Neurology
2003;60:1631–7.
13. Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in
patients with partial seizures: a novel evaluation of ﬂexible-dose and ﬁxed-
dose treatment in a double-blind, placebo-controlled study. Epilepsia
2005;46:1926–36.
14. French JA. Proof of efﬁcacy trials: endpoints. Epilepsy Research 2001;45:53–6.
15. Zigmond A, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psy-
chiatrica Scandinavica 1983;67:361–70.
16. Guy W. ECDEU assessment manual for psychopharmacology. revised ed.
Washington, DC: US Department of Health, Education, and Welfare; 1976.
17. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology
2002;58(Suppl. 5):S9–19.
18. Carreno M, Gil-Nagel A, Sanchez JC, Elices E, Serratosa JM, Salas-Puig J, et al.
Strategies to detect adverse effects of antiepileptic drugs in clinical practice.
Epilepsy & Behavior 2008;13:178–83.
19. Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of
epilepsy and its psychosocial correlates: ﬁndings from a U.K. community study.
Epilepsia 1996;37:148–61.
20. Ettinger AB, Weisbrot DM, Nolan EE, Gadow KD, Vitale SA, Andriola MR, et al.
Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia
1998;39:595–9.
21. Jones JE, Hermann BP, Barry JJ, Gilliam F, Kanner AM, Meador KJ. Clinical
assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter
investigation. The Journal of Neuropsychiatry and Clinical Neurosciences
2005;17:172–9.
22. Choi-Kwon S, Chung C, Kim H, Lee S, Yoon S, Kho H, et al. Factors affecting the
quality of life in patients with epilepsy in Seoul, South Korea. Acta Psychiatrica
Scandinavica 2003;108:428–34.
23. Johnson EK, Jones JE, Seidenberg M, Hermann BP. The relative impact of anxiety,
depression, and clinical seizure features on health-related quality of life in
epilepsy. Epilepsia 2004;45:544–50.
24. Betts T. Psychiatric disorder in epilepsy. In: Duncan JS, Sisodiya SM, Smalls JE,
editors. Epilepsy 2001. From science to patient. Oxford: International League
Against Epilepsy; 2001. p. 257–60.
25. Ryvlin P, Perucca E, Rheims S. Pregabalin for the management of partial
epilepsy. Neuropsychiatric Disease and Treatment 2008;4:1211–24.
26. Ryvlin P, Ka¨lvia¨inen R, Von Raison F, Giordano S, Emir B, Chatamra K. Pregabalin
in partial seizures: a pragmatic 21-week, open-label study (PREPS). European
Journal of Neurology )2010;(January 25). [Epub ahead of print].
27. Ramsay RE, Perucca E, Robbins J, Barrett JA, Spiegel K. Rapid onset of seizure
suppression with pregabalin adjunctive treatment in patients with partial
seizures. Epilepsia 2009;50:1891–8.
28. Lee BI, Yi S, Hong SB, Kim MK, Lee SA, Lee SK, et al. Pregabalin add-on therapy
using a ﬂexible, optimized dose schedule in refractory partial epilepsies: a
double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia
2009;50:464–74.
29. Valentin A, Moran N, Hadden R, Oakes A, Elwes R, Delamont R, et al. Pregabalin
as adjunctive therapy for partial epilepsy: an audit study in 96 patients from the
South East of England. Seizure 2009;18:450–2.
30. Carren˜o M, Maestro I, Molins A, Donaire A, Falip M, Becerra JL, et al. Pregabalin
as add-on therapy for refractory partial seizures in every day clinical practice.
Seizure 2007;16:709–12.
